Physicians' Academy for Cardiovascular Education

Protecting the heart and the kidney

Slides (presentation) - Oct. 7, 2012

Protecting the heart and the kidney: Implications from the SHARP trial

Selection of slides prepared & presented by:
Christina Reith, MD, Clinical Trials Service Unit, University of Oxford, Oxford, United Kingdom
at PACE Lipid Master Class
Budapest, September 21-22, 2012

View presentation, click on images

Protecting the heart and the kidney
Outline of presentation
Cholesterol Treatment Trialists (CTT) Collaboration
CTT meta analysis
CTT: Similar relative reductions in
Cardio-renal phenotype
Dialysis patients
CTT: Previous lack of evidence
4D trial
AURORA trial
SHARP designed to fill
Study design of sharp
LDL lowering regimen in SHARP
SHARP: Sensitive to potential benefits
SHARP: Wide inclusion criteria
SHARP: Study Design
SHARP: Baseline characteristics
Renal status at randomization
Lipid profile (mg/dL) at randomization
Impact of net compliance
SHARP: Muscle safety
SHARP: Liver safety
SHARP: Cancer incidence
No beneficial (or adverse) effect on
Key outcome: Major Atherosclerotic Events
Benefit for both MAEs and MVEs
SHARP consistent with
Comparing 4D, AURORA and SHARP
4D, AURORA and SHARP
4D, AURORA and SHARP
MAJOR ATHEROSCLEROTIC EVENTS
SHARP: Major Atherosclerotic Events
SHARP: Major Atherosclerotic Events
SHARP: Major Atherosclerotic Events by CKD stage
CTT: Effect on major vascular/atherosclerotic events
SHARP: Effects on Major Atherosclerotic Events
SHARP: Summary of findings
SHARP: Public health impact of findings

Share this page with your colleagues and friends: